On October 2, 2025, Microbot Medical Inc. announced that the Japanese Patent Office granted the company its first patent in Japan, covering the core LIBERTY® Endovascular Robotic System technology, which includes a compact robotic device for driving and manipulating elongated surgical tools.
The patent grant expands Microbot’s global intellectual‑property portfolio, adding to recent patents received in the United States, China and Israel over the past 90 days. This broadened IP protection underpins the company’s strategy to enter markets that traditionally accept FDA‑cleared devices, such as Japan.
Microbot also highlighted that it received FDA 510(k) marketing clearance for the LIBERTY system on September 8, 2025, and is targeting an estimated 2.5 million peripheral endovascular procedures in the U.S. annually. The Japanese patent strengthens the company’s ability to monetize its technology in a new, high‑volume market.
The grant enhances Microbot’s competitive moat by securing exclusive rights to its disposable robotic platform, potentially accelerating commercial launch plans and supporting future revenue growth in Japan and other global markets.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.